Document:

Supplemental Executive Retirement Plan

 Exhibit 10.1 

EXECUTION COPY 

CITADEL BROADCASTING CORPORATION 

SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN 

Participant: Farid Suleman 

Effective June 3, 2010 

 CITADEL BROADCASTING CORPORATION 

SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN 

Participant: Farid Suleman 

Effective as of June 3, 2010 

TABLE OF CONTENTS 
  

			
	 Article I - Definitions
	  	2
		
	 Article II - Eligibility for and Amount of Benefits
	  	4
		
	 Article III - Forms and Commencement of Benefits
	  	5
		
	 Article IV - Beneficiaries; Participant Data
	  	6
		
	 Article V - Amendment and Termination
	  	7
		
	 Article VI - Administration
	  	7
		
	 Article VII - Miscellaneous
	  	9
		
	 Article VIII - The Trust
	  	10

  

 i 

 CITADEL BROADCASTING CORPORATION 

SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN 

Participant: Farid Suleman 

Adopted and Effective as of June 3, 2010 (the “Effective Date”) 

This Citadel Broadcasting Corporation Supplemental Executive Retirement Plan for Farid Suleman (the “Plan”) is adopted by
Citadel Broadcasting Corporation’s Compensation Committee (“Citadel”), a Delaware corporation. The purpose of the Plan is to offer the Plan’s only participant, Farid Suleman, supplemental retirement benefits. The Plan is intended
to be an unfunded “top-hat” pension Plan that provides deferred compensation to a select group of management or highly compensated individuals. The Plan is intended to comply with the requirements of section 409A of the Code, as added by
the American Jobs Creation Act of 2004, and the Treasury regulations or any other authoritative guidance issued thereunder (collectively, “Section 409A”). 

ARTICLE I 

DEFINITIONS 

When used herein, the following terms shall have the meanings below unless the context clearly indicates otherwise: 

1.1 “Administrator” means the person or committee appointed by the Compensation Committee of the Board (the
“Committee”) to be responsible for the operation and administration of the Plan. The Committee may at any time and from time to time remove the person or committee appointed as Administrator and may appoint a new Administrator. 

1.2 “Annual Bonus” means the annual cash incentive bonus earned by the Participant for each Plan Year during the
Determination Period, regardless of when actually paid. If the Participant elects to forfeit an Annual Bonus, such Annual Bonus shall nevertheless be taken into account if the Committee determines that it was, or would have been, earned. 

1.3 “Base Salary” means the Participant’s base salary for each Plan Year in the Determination Period, without
giving effect to any deferral election. 
 1.4 “Beneficiary” means any person or persons so designated in
accordance with the provisions of Article IV. 
 1.5 “Benefit Commencement Date” means, with respect to each
payment required to be made to the Participant under this Plan, the date the payment is required to be made to the Participant hereunder. 

1.6 “Board of Directors” means the Board of Directors of Citadel. 

1.7 “Code” means the Internal Revenue Code of 1986 and the regulations thereunder, as amended from time to time.

 1.8 “Determination Period” means the five most recently completed Plan Years ending prior to the Benefit
Commencement Date. 
  

 2 

 1.9 “Disability” means a period of disability during which the Participant
(i) has been susbstantially unable to perform the his material duties hereunder by reason of illness, physical or mental disability or other similar incapacity, which inability shall continue for one-hundred eighty (180) consecutive days
or two-hundred-seventy (270) days in any twenty-four (24) month period. 
 1.10 “Employer” means
Citadel and its affiliates. 
 1.11 “Final Average Compensation” means the sum of the Participant’s
(i) average annual Base Salary for the five Plan Years during the Determination Period and (ii) average Annual Bonus for the five Plan Years during the Determination Period. 

1.12 “First Date of Eligibility” means Effective Date. 

1.13 “Involuntary Termination of Employment” means termination of the Participant’s employment with the Employer
(i) by the Employer other than for Cause; or (ii) by the Participant with Good Reason, (both as defined and described in Section 26 of the Employment Agreement effective June 3, 2010 between Citadel Broadcast Corporation and
Farid Suleman). 
 1.14 “Normal Retirement Age” means the date on which the Participant attains the age of 65.

 1.15 “Offsets” means any benefits accrued under any Company-sponsored retirement plan (other than the Plan)
that are attributable to Employer contributions (other than salary deferral contributions). 
 1.16
“Participant” means Farid Suleman, CEO of Citadel Broadcasting Corporation. 
 1.17 “Plan”
means this Citadel Broadcasting Supplemental Executive Retirement Plan – Participant: Farid Suleman. 
 1.18 “Plan
Year” means the twelve (12) month period ending on December 31. 
 1.19 “Section 409A” means
Code section 409A and the Treasury regulations or other authoritative guidance issued thereunder. 
 1.20 “Separation
from Service” means separation from service within the meaning of Section 409A, treating as a Separation from Service the Participant’s death, termination due to Disability and/or an anticipated permanent reduction in the level of
bona fide services to twenty percent (20%) or less of the average level of bona fide services performed over the immediately preceding thirty-six (36) month period (or the full period during which the Participant performed services for the
Employer, if that is less than thirty-six (36) months). For this purpose, upon a sale or other disposition of the assets of the Employer to an unrelated purchaser, if the Participant is providing services to the purchaser after and in
connection with the purchase transaction, the Board of Directors reserves the right, to the extent permitted by Section 409A, to determine that the Participant has not experienced a Separation from Service. 

1.21 “Citadel” means Citadel Broadcasting Corporation and any successor to it. 

 

 3 

 1.22 “Trust” means any trust fund established pursuant to the Plan.

 1.23 “Trustee” means the trustee named in the agreement establishing the applicable Trust and such successor
and/or additional trustees as may be named pursuant to the terms of the agreement establishing the applicable Trust. 
 1.24
“Vested Percentage” means the product of 10% and the Participant’s completed Years of Service (not to exceed 10); provided that the Vested Percentage shall be 100% if the Participant’s Separation from service is due to
death, Disability or an Involuntary Termination of Employment. 
 1.25 “Year of Service” means each twelve
(12) consecutive month period during the Participant’s employment with the Employer following the Participant’s original date of hire on March 4, 2002, including any partial Years of Service (expressed in terms of completed
months) for the applicable portion of the year to be considered. On the Effective Date, the Participant was credited with 8.25 Years of Service. 

ARTICLE II 

ELIGIBILITY FOR AND AMOUNT OF BENEFITS 

2.1 Eligibility. This Plan has the limited purpose of providing for the funding and payment of a supplemental
executive retirement benefit for the Participant. Therefore, the Participant is the only eligible participant under the provisions of this Plan and his participation and eligibility has been approved by the Committee. 

2.2 Supplemental Plan Benefit. 

(a) Normal Retirement Benefit. Upon the Participant reaching his Normal Retirement Age, and for any benefits accrued after
Normal Retirement Age, the Supplemental Plan Benefit shall be equal to the product of (A) the Participant’s Vested Percentage and (B) an amount equal to (i) minus (ii) minus (iii), where (i), (ii), and (iii) are:

 (i) The present value of a single life annuity paying the Participant four percent (4%) times Years of Service (to a
maximum of 25 years) times the Participant’s Final Average Compensation (to a maximum of one hundred percent (100%) of the Participant’s Final Average Compensation). 

(ii) The present value of the Participant’s Offsets. 

(iii) The accumulated value of any prior distributions under this Plan. 

(b) Benefit Upon a Separation from Service. Upon any Separation from Service, the Participant shall be entitled to any
unpaid Supplemental Plan Benefit determined pursuant to Section 2.2(a) as of his Separation from Service; provided that if such Separation from Service occurs before the Participant has attained his Normal Retirement Age, the Participant’s
Supplemental Plan Benefit shall be determined pursuant to Section 2.2(a) as of his Separation from Service and shall be reduced by four percent (4%) per year for each year (or fraction thereof) prior to 65 that such benefit would be paid.
In determining the value of Offsets to the Supplemental Plan Benefit commencing prior to the Participant’s Normal Retirement Date, no further accruals shall be assumed but future investment earnings shall be assumed using the assumptions set
forth in Section 2.3. 
  

 4 

 (c) Benefit Payment. Any amount payable hereunder shall be paid in
accordance with Section 3.2. 
 2.3 Actuarial Equivalent. In determining present value hereunder, any
amount expressed as an annuity (e.g., the amounts described in Sections 2.2 (a)(i), (ii) and (iii)) shall be determined using as the interest rate the “applicable interest rate,” as such term is defined under section 417(e)(3)(C) of
the Code for the second month preceding the calendar year in which the Participant or Beneficiary receives payment (in accordance with Section 3.2) and (2) the mortality table will be the “applicable mortality table,” as such
term is defined under section 417(e)(3)(B) of the Code. The “applicable interest rate” means the adjusted first, second and third segment rates applied under rules similar to section 430(h)(2)(C) of the Code, computed without regard to a
24-month average. For purposes of projecting the value of the Employer contributions to Normal Retirement Age under Section 2.2(b), the assumed investment return rate shall be 5.0%. 

ARTICLE III 

FORM AND COMMENCEMENT OF BENEFITS 

3.1 Form of Benefits. Supplemental Plan Benefits payable to the Participant or a Beneficiary pursuant to Article II
shall be in the form of a lump sum cash payment. 
 3.2 Commencement of Benefits. Subject to Sections 3.4
and 3.5, the Supplemental Plan Benefits shall be payable to the Participant by no later than the fifteenth day of the third month following the earlier to occur of (i) the Participant attaining his Normal Retirement Age or (ii) the
Participant’s Separation from Service; provided that any Supplement Plan Benefit earned by the Participant after attaining his Normal Retirement Age shall be paid no later than the fifteenth day of the third month following his subsequent
Separation from Service. 
 3.3 Permitted Accelerations. The Committee in its sole discretion (without any
direct or indirect election on the part of the Participant), may accelerate payments under the Plan to the extent permitted under Section 409A (such as, for example, as provided in Section 1.409A-3(j)(4) of the Treasury regulations, to
comply with domestic relations orders or certain conflict of interest rules, to pay employment taxes, to make a lump sum cash out of certain de minimis amounts that are less than the applicable dollar amount under Code Section 402(g)(1)(B), or
to make payments upon income inclusion under Section 409A). 
 3.4 Delay in Payment. If Citadel
reasonably anticipates that any payment scheduled to be made hereunder would violate securities laws (or other applicable laws) or jeopardize the ability of the Employer to continue as a going concern if paid as scheduled, then Citadel may defer
that payment. In addition, Citadel may, in its discretion, delay a payment upon such other events and conditions as the IRS may prescribe. The amounts so deferred shall be distributed to the Participant or his or her Beneficiary (in the event of the
Participant’s death) at the earliest possible date on which Citadel reasonably anticipates that such violation or material harm would be avoided or as otherwise prescribed by the IRS. Any application of this Section 3.4 must comply with
Section 409A. 
  

 5 

 3.5 Section 409A Delay. Notwithstanding anything herein to the
contrary, if, at the time any payment is payable to the Participant under this Plan as a result of the Participant’s Separation from Service (other than due to the Participant’s death) , Citadel or any company in the affiliated group in
which Citadel’s financial statements are consolidated in accordance with generally accepted accounting principles has a class of equity securities traded on an established domestic or foreign securities market or otherwise and the Participant
is designated a “specified person” (as such term is defined in Section 409A and the regulations promulgated thereunder) on a list prepared by the Employer periodically pursuant to Section 409A and the regulations promulgated
thereunder, then during the six month period from and after the date of the Participant’s Separation from Service the amount payable to the Participant pursuant to this shall be withheld during such period and paid to the Participant in a lump
sum upon the expiration of six months after the date of Separation from Service (or , if earlier than the end of such six month period, upon the Participant’s death). 

ARTICLE IV 

BENEFICIARIES; PARTICIPANT DATA 

4.1 Designation of Beneficiaries. In the event of the Participant’s death, any unpaid benefit under this Plan
shall be paid to the Participant’s Beneficiary. The Participant from time to time may designate any person or persons (who may be named contingently or successively) to receive such benefits as may be payable under the Plan upon or after the
Participant’s death, and such designation may be changed from time to time by the Participant by filing a new designation. Each designation by the Participant will revoke all prior designations by the Participant, shall be in the form
prescribed by the Administrator and will be effective only when filed in writing with the Administrator during the Participant’s lifetime. In the absence of a valid Beneficiary designation, or if, at the time any benefit payment is due to a
Beneficiary, there is no living Beneficiary validly named by the Participant, the Committee shall pay any such benefit payment to the Participant’s surviving spouse (who is the spouse legally married to the Participant on the Participant’s
date of death), if then living, otherwise to the Participant’s estate. 
 4.2 Information to be Furnished by the
Participant and Beneficiaries; Inability to Locate Participant or Beneficiaries. Any communication, statement or notice addressed to the Participant or to a Beneficiary at his last post office address as shown on Citadel’s records shall
be binding on the Participant or Beneficiary for all purposes of the Plan. Neither the Trustee, nor the Committee nor the Employer shall be obliged to search for the Participant or any Beneficiary beyond the sending of a registered letter to such
last known address. If the Administrator notifies the Participant or any Beneficiary that is entitled to an amount under the Plan and the Participant or Beneficiary fails to claim such amount or make his location known to the Administrator, then,
except as otherwise required by law, the amount payable shall be deemed to be a forfeiture and paid to Citadel. If a benefit payable to the Participant or any Beneficiary is subject to escheat pursuant to applicable state law, Citadel shall not be
liable to any person for any payment made in accordance with such law. 
  

 6 

 ARTICLE V 

AMENDMENT AND TERMINATION 

5.1 Amendment or Termination. The Committee intends to continue the Plan indefinitely but reserves the right
to amend or terminate the Plan by or pursuant to action of the Board of Directors or the Committee when, in the sole opinion of the Board of Directors or the Committee, an amendment or termination is advisable. No amendment or termination of the
Plan shall directly or indirectly deprive the Participant or his Beneficiary of all or any portion of any accrued Supplemental Plan Benefit. Without limiting the generality of the foregoing, the Committee specifically reserves the right to terminate
and liquidate the Plan, in its discretion and by action of the Committee, within the thirty (30) days preceding or the twelve (12) months following a “change in control event” (as defined in Section 409A); provided, however,
that such termination and liquidation must be irrevocable and shall be permitted only if all arrangements sponsored by Citadel or its affiliated entities that are required to be aggregated with the Plan pursuant to Section 7.9 are also
irrevocably terminated and liquidated with respect to the Participant therein who is employed by Citadel that has experienced the change in control event, so that the Participant and all participants under those other arrangements who are employed
by the Employers that have experienced the change in control event are required to receive all amounts of compensation deferred under the terminated and liquidated arrangements within twelve (12) months of the date Citadel takes irrevocable
action to terminate and liquidate the arrangements. Upon termination of the Plan, the Participant shall be treated as if he had experienced an Involuntary Termination of Employment on the date of such amendment; provided, however, any distribution
made upon a termination of the Plan shall be distributed in accordance with the requirements, restrictions and limitations of Section 1.409A-3(j)(4)(ix) of the Treasury regulations. 

5.2 Amendments Required By Law. Notwithstanding the provisions of Section 5.1, the Plan may be amended at any
time, retroactively if required, if found necessary, in the opinion of the Committee, in order to ensure that the Plan is characterized as a non-tax-qualified Plan of deferred compensation as described under Code, to ensure that the Trust is
characterized as a grantor trust as described in the Code, to conform the Plan to the provisions of Section 409A and to conform the Plan and the Trust to the requirements of any other applicable law; except to the extent that Section 409A
requires that this Section be disregarded because it purports to nullify Plan terms that are not in compliance with Section 409A. No such amendment shall be considered prejudicial to any interest of the Participant or a Beneficiary. 

5.3 Prohibited Acceleration/Distribution Timing. This Section shall take precedence over any other provision of the
Plan or this Article V to the contrary. If the timing of any distribution election would result in any tax or other penalty (other then ordinary payable Federal, state and payroll taxes), which tax or penalty can be avoided by payment of the
distribution at a later time, then the distribution shall be made on (or as soon as practicable after) the first date on which such distributions can be made without such tax or penalty; except to the extent that Section 409A requires that this
Section 5.3 be disregarded because it purports to nullify Plan terms that are not in compliance with Section 409A. 

ARTICLE VI 

ADMINISTRATION 

6.1 Administrator. The Plan shall be administered by the Administrator, which shall have the authority to interpret
the Plan, and to determine the nature and amount of benefits. Any construction or interpretation of the Plan and any determination of fact in administering the Plan made in good faith by the Administrator shall be final and conclusive for all Plan
purposes. 
  

 7 

 6.2 Claims Procedure. 

(a) Initial Claim. Either the Participant or Beneficiary of the Participant if he dies prior to the final
distribution under this Plan (“Claimant”) may deliver to the Administrator a written claim for a determination with respect to the amounts distributable to such Claimant from the Plan. If such a claim relates to the contents of a notice
received by the Claimant, the claim must be made within 60 days after such notice was received by the Claimant. All other claims must be made within 180 days of the date on which the event that caused the claim to arise occurred. The claim must
state, in detail, the determination desired by the Claimant. 
 (b) Notification of Decision. The
Administrator shall consider a Claimant’s claim within a reasonable time, and shall notify the Claimant in writing: 
 (i)
That the Claimant’s requested determination has been made, and that the claim has been allowed in full; or 
 (ii) That
the Administrator has reached a conclusion contrary, in whole or in part, to the Claimant’s requested determination, and such notice must set forth in a manner calculated to be understood by the Claimant: 

(iii) The specific reason(s) for the denial of the claim, or any part of it; 

(iv) Specific reference(s) to pertinent provisions of the Plan upon which such denial was based; 

(v) A description of any additional material or information necessary for the Claimant to perfect the claim, and an explanation of why
such material or information is necessary; and 
 (vi) An explanation of the claim review procedure set forth in the Plan
document. 
 (c) Review of a Denied Claim. Within 60 days after receiving a notice from the Administrator
that a claim has been denied, in whole or in part, a Claimant (or the Claimant’s duly authorized representative) may file with the Committee a written request for a review of the denial of the claim. Thereafter, but not later than 30 days after
the review procedure began, the Claimant (or the Claimant’s duly authorized representative): 
 (i) May review pertinent
documents; 
 (ii) May submit written comments or other documents; and/or 

(iii) May request a hearing, which the Administrator, in its sole discretion, may grant. 

 

 8 

 (d) Decision on Review. The Administrator shall render its decision on
review promptly, and not later than 60 days after the filing of a written request for review of the denial, unless a hearing is held or other special circumstances require additional time, in which case the Administrator’s decision must be
rendered within 120 days after such date. Such decision must be written in a manner calculated to be understood by the Claimant, and it must contain: 

(i) Specific reasons for the decision; 

(ii) Specific reference(s) to the pertinent Plan provisions upon which the decision was based; and 

(iii) Such other matters as the Administrator deems relevant. 

(e) Legal Action. A Claimant’s compliance with the foregoing provisions of this Article is a mandatory
prerequisite to a Claimant’s right to commence any legal action with respect to any claim for benefits under this Plan. 

ARTICLE VII 

MISCELLANEOUS 

7.1 No Effect on Employment Rights. Nothing contained herein will confer upon the Participant the right to be
retained in the service of the Employer nor limit the right of the Employer to discharge or otherwise deal with the Participant without regard to the existence of the Plan. 

7.2 Funding. Neither the Participant, any Beneficiary nor any other person shall have any interest in any particular
assets of the Employer by reason of the right to receive a benefit under the Plan. To the extent that the Participant or any other person acquires a right to receive benefits under this Plan, such right shall be no greater than the right of any
unsecured general creditor of the Employer. 
 7.3 Spendthrift Provisions. No benefit payable under the
Plan shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, or charge prior to actual receipt thereof by the payee; and any attempt so to anticipate, alienate, sell, transfer, assign, pledge,
encumber, or charge prior to such receipt shall be void; and Citadel shall not be liable in any manner for or subject to the debts, contracts, liabilities, engagements or torts of any person entitled to any benefit under the Plan. 

7.4 State Law. The Plan is established under and will be construed according to the laws of the State of New York.

 7.5 Incapacity of Recipient. In the event that the Participant or any Beneficiary is declared
incompetent or otherwise incapacitated and a conservator, guardian or other person legally charged with the care of the person or the estate of the Participant or the Beneficiary is appointed, any benefits under the Plan to which the Participant or
his or her Beneficiary is entitled shall be paid to the conservator, guardian or other person legally charged with the care of the Participant. Except as provided in the preceding sentence, should the Administrator, in its discretion, determine that
the Participant or any Beneficiary is unable to manage personal affairs, the Administrator may make distributions to any person for the benefit of the Participant or any Beneficiary. 

 

 9 

 7.6 Impact on Other Plans. This Plan shall not affect the
Participant’s rights under, or replace, other retirement, welfare or similar benefits, except if the contrary is provided herein or in such other benefit Plans. 

7.7 Representations. Neither Citadel nor any Employer represents or guarantees that any particular federal or state
income, payroll, personal property or other tax consequence will result from participation in this Plan. The Participant should consult with professional tax advisors to determine the tax consequences of his participation. 

7.8 Aggregation of Employers. If the Employer is a member of a controlled group of corporations or a group of trades
or businesses under common control (as described in Code sections 414(b) or (c), but substituting a fifty percent (50%) ownership level for the eighty percent (80%) level set forth in those Code sections), all members of the group shall be
treated as a single Employer for purposes of whether there has occurred a Separation from Service and for any other purposes under the Plan as Section 409A shall require. For purposes of Section 5.1, in the case of a change in control
event, the entities to be treated as a single Employer shall be determined immediately following the change in control event. 

7.9 USERRA. Notwithstanding anything herein to the contrary, any distribution election provided to the Participant as
necessary to satisfy the requirements of the Uniformed Services Employment and Reemployment Rights Act of 1994, as amended, shall be permissible hereunder. 

7.10 Aggregation of Plans. If the Employer offers other nonaccount balance deferred compensation Plans in addition to the
Plan, those Plans together with the Plan shall be treated as a single Plan to the extent required under Section 409A for purposes of cashing out de minimus amounts pursuant to Section 3.3 and for any other purposes under the Plan as
Section 409A shall require. 
 ARTICLE VIII 

THE TRUST 

8.1 Establishment of the Trust. Citadel may establish a Trust with a Trustee pursuant to such terms and conditions
as may be established in a formal trust document or agreement that would be entered into between Citadel and a Trustee. The Trust shall be intended to be treated as a “grantor” trust under the Code and the establishment of any Trust shall
not be intended to cause the Participant to realize current income on amounts contributed thereto, and the Trust shall be so interpreted. 

[REMAINDER OF PAGE LEFT BLANK] 
  

 10 

 IN WITNESS WHEREOF, the Company has caused this instrument to be executed by an
authorized member this 20th day of August, 2010. 
 ATTEST: 

 

									
		 		 		 	CITADEL BROADCASTING CORPORATION
				
	 /s/ June L. Kelley
	 		 	By:	 	 /s/ Randy L. Taylor

					
	Print Name:	 	 June L. Kelley
	 		 	Print Name:	 	 Randy L. Taylor

					
		 		 		 	Title:	 	 CFO

					
		 		 		 	Date:	 	 8/20/10

  

 11exhibit4-1.htm

    EXHIBIT 4.1 

     

    COMMON STOCK PURCHASE AGREEMENT

     

    THIS COMMON
STOCK PURCHASE AGREEMENT (“Agreement”) is made and entered into as of August 16,
2010 (the “Effective
Date”),
by and between GERON CORPORATION, a Delaware corporation having its principal
place of business at 230 Constitution Drive, Menlo Park, California 94025
(“Geron”), and HONGENE BIOTECHNOLOGY LIMITED, having its principal place of
business at Room 203, Building 8, No. 500 CaoBao Road, Shanghai, China, 200233;
Tel: 0086-21-64757213, 0086-21-54971054 Fax: 0086-21-6470061 (“Manufacturer”).

     

    
      	      	A.	
            	Geron
      and Manufacturer are the parties to that certain Master Manufacturing
      Agreement dated as of March 9, 2006 (the “Supply
      Agreement”), and related Addendum Agreements (“Addendum
      Agreement”) under which Geron has agreed to purchase certain products from
      Manufacturer and Manufacturer has agreed to supply such products to Geron
      on the terms set forth therein.
	
            	  
	
            	B.	      	Pursuant to Addendum Agreement No. 6, dated as of August 16, 2010,
      and the First Amendment to the Supply Agreement, dated as of November 9,
      2007, Geron may pay the purchase price of products by delivery of shares
      of Geron’s Common Stock (the “Shares”).

    

     

    THE PARTIES AGREE AS FOLLOWS:

     

    
      	1.	
            	ISSUANCE OF SHARES;
      ADJUSTMENTS.
	 
	 	      	1.1	      	As payment of the costs specified in Addendum Agreement No. 6,
      Geron will issue and deliver certificates for 114,957 Shares. Upon
      issuance and delivery of the certificate(s) for the Shares, all Shares
      shall be duly authorized and validly issued and represent fully paid
      shares of Geron’s Common Stock.
	 
	2.	
            	CLOSING;
      DELIVERY.
	 
	 	
            	2.1	
            	The consummation of the transaction contemplated by this Agreement
      (a “Closing”) shall be held at such time
      and place as is mutually agreed upon between the parties, but in any event
      Geron shall make commercially reasonable efforts to accomplish the Closing
      no later than five (5) business days after the Effective Date hereof (the
      “Closing
      Date”). At
      the Closing, Geron shall deliver to Manufacturer one or more certificates
      representing all of the Shares, which Shares shall be issued in the name
      of Manufacturer or its designee and in such denominations as Manufacturer
      shall specify.
	 
	 	
            	2.2	
            	Geron’s obligation to issue and deliver the stock certificate(s)
      representing the Shares to Manufacturer at the Closing shall be subject to
      the following conditions, which may be waived by Geron:
	 
	 	
            	 	
            	2.2.1	      	the
      covenants and obligations that Manufacturer is required to perform or to
      comply with pursuant to this Agreement, at or prior to the Closing, must
      have been duly performed and complied with in all material respects;
      and
	 
	 	
            	 	
            	2.2.2	
            	the
      representations and warranties made by Manufacturer herein shall be true
      and correct in all material respects as of the Closing Date.
	 
	 	
            	2.3	
            	Manufacturer’s obligation to accept delivery of the stock
      certificate(s) representing the Shares at the Closing shall be subject to
      the following conditions, any one or more of which may be waived by
      Manufacturer:

    

    

    
    

    
      	
            	
            	
            	
            	2.3.1	
            	the covenants and obligations
      that Geron is required to perform or to comply with pursuant to this
      Agreement, at or prior to the Closing, must have been duly performed and
      complied with in all material respects;
	
            	
            	
            	
            	
            	
            	 
	
            	
            	
            	
            	2.3.2	
            	Geron shall have available under
      its Certificate of Incorporation sufficient authorized shares of Common
      Stock to issue the Shares to Manufacturer; and
	
            	
            	
            	
            	
            	
            	 
	
            	
            	
            	 	2.3.3	      	the representation and warranties
      made by Geron herein shall be true and correct in all material respects as
      of the Closing Date.
	
            	
            	  
	3.	
            	RESTRICTIONS ON RESALE OF
      SHARES.
	 
	 	      	3.1	
            	Legends. Manufacturer understands and
      acknowledges that the Shares are not registered under the Securities Act
      of 1933 (the “Act”), and that under the Act and
      other applicable laws Manufacturer may be required to hold such Shares for
      an indefinite period of time. Each stock certificate representing Shares
      shall bear the following legends:
	 
	 	
            	 	      	“THE SECURITIES REPRESENTED
      HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
      AMENDED (THE “ACT”). ANY TRANSFER OF SUCH SECURITIES SHALL BE INVALID
      UNLESS A REGISTRATION STATEMENT UNDER THE ACT IS IN EFFECT AS TO SUCH
      TRANSFER OR, IN THE OPINION OF COUNSEL REASONABLY ACCEPTABLE TO GERON,
      SUCH REGISTRATION IS UNNECESSARY FOR SUCH TRANSFER TO COMPLY WITH THE ACT.
      THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO THE TERMS OF THE COMMON
      STOCK PURCHASE AGREEMENT BY AND BETWEEN GERON AND MANUFACTURER DATED AS OF
      AUGUST 16, 2010. A COPY OF THE AGREEMENT CAN BE OBTAINED FROM THE
      SECRETARY OF GERON.”
	 
	 	
            	3.2	
            	Limits on
      Sales.
      Manufacturer agrees that if it decides to resell some or all of the
      Shares, it will do so only through orderly sales executed through a
      top-tier brokerage house, and in an appropriate manner based upon whether
      the shares are registered or unregistered, i.e., on the Nasdaq Global Market or
      in a Rule 144A compliant transaction. Manufacturer further agrees that it
      will not engage in short selling with respect to the Stock.
	 
	 	
            	3.3	
            	Further Limitations.
      Geron
      shall not be required (i) to transfer on its books any Shares that have
      been sold or otherwise transferred in violation of any of the provisions
      of this Agreement or applicable securities laws; or (ii) to treat as owner
      of such Shares or to accord the right to vote or pay dividends to any
      purchaser or other transferee to whom such Shares shall have been so
      transferred in violation of any of the provisions of this Agreement or
      applicable securities laws.
	 
	4.	
            	REGISTRATION
      RIGHTS
	 
	 	
            	4.1	
            	Geron agrees to make
      commercially reasonable efforts to file with the Securities and Exchange
      Commission (the “Commission”) within ten (10) business
      days after the Closing Date, a registration statement under the Act (the
      “Registration
      Statement”), on Form S-3 or other appropriate form, so as to permit a
      non-underwritten public offering and resale of the Shares under the Act by
      Manufacturer. Geron agrees to diligently pursue making the Registration
      Statement effective. Geron will make commercially reasonable efforts to
      notify Manufacturer of the effectiveness of the Registration Statement
      within one (1) business day of receiving notice from the Commission
      declaring the Registration Statement
effective.

    

    

    
    

    
      	   	      	4.2	      	Geron will make commercially reasonable efforts to maintain the
      Registration Statement and any post-effective amendment thereto filed
      under this Section 4 effective under the Act until the earliest of (i) the
      date that none of the Shares covered by such Registration Statement are
      issued and outstanding, (ii) the date that all of the Shares have been
      sold pursuant to such Registration Statement, (iii) the date Manufacturer
      receives an opinion of counsel from Geron, which counsel shall be
      reasonably acceptable to Manufacturer, that the Shares may be sold under
      the provisions of Rule 144 or any similar provision then in effect under
      the Act without limitation as to volume, or (iv) the date that all Shares
      have been otherwise transferred to persons who may trade such shares
      without restriction under the Act, and Geron has delivered a new
      certificate or other evidence of ownership for such securities not bearing
      a restrictive legend, or (v) the date all Shares may be sold at any time,
      without volume or manner of sale limitations pursuant to Rule 144 or any
      similar provision then in effect under the Act in the opinion of counsel
      to Geron, which counsel shall be reasonably acceptable to
      Manufacturer.
	
            	
            	 
	
            	
            	4.3	
            	Geron,
      at its expense, shall furnish to Manufacturer with respect to the Shares
      registered under the Registration Statement such reasonable number of
      copies of the Registration Statement, prospectuses and preliminary
      prospectuses in conformity with the requirements of the Act and such other
      documents as Manufacturer may reasonably request, in order to facilitate
      the public sale or other disposition of all or any of the Shares by
      Manufacturer, provided, however, that the obligation of Geron to deliver
      copies of prospectuses or preliminary prospectuses to Manufacturer shall
      be subject to the receipt by Geron of reasonable assurances from
      Manufacturer that Manufacturer will comply with the applicable provisions
      of the Act and of such other securities or blue sky laws as may be
      applicable in connection with any use of such prospectuses or preliminary
      prospectuses.
	
            	
            	 
	
            	
            	4.4	
            	All
      fees, disbursements and out-of-pocket expenses and costs incurred by Geron
      in connection with the preparation and filing of the Registration
      Statement under Section 4.1 and in complying with applicable securities
      and Blue Sky laws (including, without limitation, all attorneys' fees of
      Geron) shall be borne by Geron. Manufacturer shall bear the cost of all
      fees and expenses of Manufacturer’s counsel.
	
            	
            	 
	
            	
            	4.5	
            	Geron
      will advise Manufacturer promptly after it shall receive notice or obtain
      knowledge of the issuance of any stop order by the Commission delaying or
      suspending the effectiveness of the Registration Statement or of the
      initiation of any proceeding for that purpose, and Geron will use its
      commercially reasonable efforts to prevent the issuance of any stop order
      or to obtain its withdrawal as promptly as possible if such stop order
      should be issued.
	
            	
            	 
	
            	
            	4.6	
            	With a
      view to making available to Manufacturer the benefits of Rule 144 (or its
      successor rule) and any other rule or regulation of the Commission that
      may at the time permit Manufacturer to sell the Shares to the public
      without registration, Geron covenants and agrees to make commercially
      reasonable efforts to: (i) make and keep public information available, as
      those terms are understood and defined in Rule 144, until the earliest of
      (A) such date as all of the Shares may be resold pursuant to Rule 144 or
      any other rule of similar effect or (B) such date as all of the Shares
      shall have been resold; and (ii) file with the Commission in a timely
      manner all reports and other documents required of Geron under the Act and
      under the Securities Exchange Act of 1934, as amended (the “Exchange
      Act”).
	
            	
            	 
	
            	
            	4.7	
            	Manufacturer will cooperate with Geron in all respects in
      connection with this Agreement, including timely supplying all information
      reasonably requested by Geron (which shall include all information
      regarding Manufacturer and proposed manner of sale of the Shares required
      to be disclosed in any Registration Statement) and executing and returning
      all documents reasonably requested in connection with the registration and
      sale of the Shares and entering into and performing their obligations
      under any underwriting agreement, if the offering is an underwritten
      offering, in usual and customary form, with the managing underwriter or
      underwriters of such underwritten offering. Nothing in this Agreement
      shall obligate Manufacturer to consent to be named as an underwriter in
      any Registration Statement.

    

    

    
    

    
      	5.	 	INDEMNIFICATION.
	 
	 	      	5.1	      	Geron agrees to indemnify and hold harmless Manufacturer (and each
      person, if any, who controls Manufacturer within the meaning of Section 15
      of the Act, and each officer and director of Manufacturer) against any and
      all losses, claims, damages or liabilities (or actions or proceedings in
      respect thereof), joint or several, directly or indirectly based upon or
      arising out of (i) any untrue statement or alleged untrue statement of any
      material fact contained in the Registration Statement, any preliminary
      prospectus, final prospectus or summary prospectus contained therein or
      used in connection with the offering of the Shares, or any amendment or
      supplement thereto, or (ii) any omission or alleged omission to state a
      material fact required to be stated therein or necessary to make the
      statements therein not misleading; and Geron will reimburse each such
      indemnified party for any legal or any other expenses reasonably incurred
      by them in connection with investigating, preparing, pursuing or defending
      any such loss, claim, damage, liability, action or proceeding, except
      insofar as any such loss, claim, damage, liability, action, proceeding or
      expense (A) arises out of or is based upon an untrue statement or alleged
      untrue statement or omission or alleged omission made in the Registration
      Statement, any such preliminary prospectus, final prospectus, summary
      prospectus, amendment or supplement in reliance upon and in conformity
      with written information furnished to Geron by or on behalf of
      Manufacturer or such other person expressly for use in the preparation
      thereof, (B) the failure of Manufacturer to comply with its covenants and
      agreements contained in Sections 7.1 or 7.5.2 hereof or (C) any
      misstatement or omission in any prospectus that is corrected in any
      subsequent prospectus that was delivered to Manufacturer prior to the
      pertinent sale or sales by Manufacturer. Such indemnity shall remain in
      full force and effect, regardless of any investigation made by such
      indemnified party and shall survive the transfer of the Shares by
      Manufacturer.
	 
	 	
            	5.2	
            	Manufacturer agrees to indemnify and hold harmless Geron (and each
      person, if any, who controls Geron within the meaning of Section 15 of the
      Act, and each officer and director of Geron) from and against losses,
      claims, damages or liabilities (or actions or proceedings in respect
      thereof), joint or several, directly or indirectly based upon or arising
      out of, (i) any failure of Manufacturer to comply with the covenants and
      agreements contained in Sections 7.1 and 7.5.2 hereof or (ii) any untrue
      statement of a material fact contained in the Registration Statement or
      any omission of a material fact required to be stated in the Registration
      Statement or necessary in order to make the statements in the Registration
      Statement not misleading if such untrue statement or omission was made in
      reliance upon and in conformity with written information furnished to
      Geron by or on behalf of Manufacturer specifically for use in preparation
      of the Registration Statement; provided, however, that Manufacturer shall
      not be liable in any such case for (A) any untrue statement or omission in
      the Registration Statement, prospectus, or other such document which
      statement is corrected by Manufacturer and delivered to Geron prior to the
      sale from which such loss occurred, (B) any untrue statement or omission
      in any prospectus which is corrected by Manufacturer in any subsequent
      prospectus, or supplement or amendment thereto, and delivered to Geron
      prior to the sale or sales from which a loss or liability arose, or (C)
      any failure by Geron to fulfill any of its obligations under Section 5.1
      hereof.

    

    

    
    

    
      	 	
            	5.3	
            	Promptly after receipt by any indemnified person of a notice of a
      claim or the beginning of any action in respect of which indemnity is to
      be sought against an indemnifying person pursuant to this Section 5, such
      indemnified person shall notify the indemnifying person in writing of such
      claim or of the commencement of such action, but the omission to so notify
      the indemnifying party will not relieve it from any liability which it may
      have to any indemnified party under this Section 5 (except to the extent
      that such omission materially and adversely affects the indemnifying
      party’s ability to defend such action) or from any liability otherwise
      than under this Section 5. Subject to the provisions hereinafter stated,
      in case any such action shall be brought against an indemnified person,
      the indemnifying person shall be entitled to participate therein, and, to
      the extent that it shall elect by written notice delivered to the
      indemnified party promptly after receiving the aforesaid notice from such
      indemnified party, shall be entitled to assume the defense thereof, with
      counsel reasonably satisfactory to such indemnified person. After notice
      from the indemnifying person to such indemnified person of its election to
      assume the defense thereof, such indemnifying person shall not be liable
      to such indemnified person for any legal expense subsequently incurred by
      such indemnified person in connection with the defense thereof, provided,
      however, that if there exists or shall exist a conflict of interest that
      would make inappropriate, in the reasonable opinion of counsel to the
      indemnified person, for the same counsel to represent both the indemnified
      person and such indemnifying person or any affiliate or associate thereof,
      the indemnified person shall be entitled to retain its own counsel at the
      expense of such indemnifying person; provided, however, that no
      indemnifying person shall be responsible for the fees and expenses of more
      than one separate counsel (together with appropriate local counsel) for
      all indemnified parties. In no event shall any indemnifying person be
      liable in respect to any amounts paid in settlement of any action unless
      the indemnifying person shall have approved the terms of such settlement.
      No indemnifying person shall, without the prior written consent of the
      indemnified person, effect any settlement of any pending or threatened
      proceeding in respect of which any indemnified person is or could have
      been a party and indemnification could have been sought hereunder by such
      indemnified person, unless such settlement includes an unconditional
      release of such indemnified person from all liability on claims that are
      the subject matter of such proceeding.
	 
	 	
            	5.4	
            	The provisions of this Section 5 shall survive the termination of
      this Agreement.
	 
	6.	
            	REPRESENTATIONS AND
      ACKNOWLEDGEMENT OF GERON.
	 
	 	
            	Geron hereby represents,
      warrants and covenants to Manufacturer as follows:
	 
	 	      	6.1	      	Organization, Good Standing
      and Qualification. Geron is a corporation duly organized, validly existing and in
      good standing under the laws of the State of Delaware and has all
      requisite corporate power and authority to carry on its business as now
      conducted and as presently proposed to be conducted. Geron is duly
      qualified to transact business and is in good standing as a foreign
      corporation in each jurisdiction in which the failure to so qualify would
      have a material adverse effect on its business or properties.
	 
	 	
            	6.2	
            	Authorization. All corporate action on the
      part of Geron, its officers, directors and stockholders necessary for the
      authorization, execution and delivery of this Agreement, the performance
      of all obligations of Geron hereunder and the authorization, issuance and
      delivery of the Shares has been taken or will be taken prior to the
      Closing, and this Agreement, when executed and delivered will constitute
      valid and legally binding obligations of Geron, enforceable against Geron
      in accordance with its terms, except as limited by applicable bankruptcy,
      insolvency, reorganization, moratorium, fraudulent conveyance and other
      laws of general application affecting enforcement of creditors’ rights
      generally, as limited by laws relating to the availability of specific
      performance, injunctive relief or other equitable remedies.
	 
	 	
            	6.3	
            	Valid Issuance of Common
      Stock. The
      Shares, when issued, sold and delivered in accordance with the terms
      hereof for the consideration expressed herein, will be duly and validly
      authorized and issued, fully paid and nonassessable and free of
      restrictions on transfer other than restrictions on transfer under this
      Agreement and applicable state and federal securities laws.
	 
	 	
            	6.4	
            	Legal Proceedings and Orders.
      There is
      no action, suit, proceeding or investigation pending or threatened against
      Geron that questions the validity of this Agreement or the right of Geron
      to enter into this Agreement or to consummate the transactions
      contemplated hereby, nor is Geron aware of any basis for any of the
      foregoing. Geron is neither a party nor subject to the provisions of any
      order, writ, injunction, judgment or decree of any court or government
      agency or instrumentality that would affect the ability of Geron to enter
      into this Agreement or to consummate the transactions contemplated
      hereby.

    

    

    
    

    
      	7.	
            	REPRESENTATIONS AND
      ACKNOWLEDGMENTS OF MANUFACTURER.
	 
	 	
            	Manufacturer hereby
      represents, warrants, acknowledges and agrees that:
	 
	 	
            	7.1	
            	Investment. Manufacturer is acquiring
      the Shares for Manufacturer’s own account, and not directly or indirectly
      for the account of any other person. Manufacturer is acquiring the Shares
      for investment and not with a view to distribution or resale thereof,
      except in compliance with the Act and any applicable state law regulating
      securities.
	 
	 	
            	7.2	
            	Access to Information.
      Manufacturer has consulted with its own attorney, accountant, or
      investment advisor as Manufacturer has deemed advisable with respect to
      the investment and has determined its suitability for Manufacturer.
      Manufacturer has had the opportunity to ask questions of, and to receive
      answers from, appropriate executive officers of Geron with respect to the
      terms and conditions of the transactions contemplated hereby and with
      respect to the business, affairs, financial condition and results of
      operations of Geron. Manufacturer has had access to such financial and
      other information as is necessary in order for Manufacturer to make a
      fully informed decision as to investment in Geron, and has had the
      opportunity to obtain any additional information necessary to verify any
      of such information to which Manufacturer has had access. Manufacturer
      acknowledges that neither Geron nor any of its officers, directors,
      employees, agents, representatives, or advisors have made any
      representation or warranty other than those specifically expressed
      herein.
	 
	 	
            	7.3	
            	Business and Financial
      Expertise. Manufacturer further represents and warrants that it has such
      business or financial expertise as to be able to evaluate its investment
      in Geron and purchase of the Shares.
	 
	 	
            	7.4	
            	Speculative Investment.
      Manufacturer acknowledges that the investment in Geron represented
      by the Shares is highly speculative in nature and is subject to a high
      degree of risk of loss in whole or in part; the amount of such investment
      is within Manufacturer’s risk capital means and is not so great in
      relation to Manufacturer’s total financial resources as would jeopardize
      the personal financial needs of Manufacturer in the event such investment
      were lost in whole or in part.
	 
	 	
            	7.5	
            	Unregistered Securities.
      Manufacturer acknowledges that:
	 
	 	      	 	      	7.5.1	      	Manufacturer must bear the economic risk of investment for an
      indefinite period of time because the Shares have not been registered
      under the Act and therefore cannot and will not be sold unless they are
      subsequently registered under the Act or an exemption from such
      registration is available. Geron has made no agreements, covenants or
      undertakings whatsoever to register any of the Shares under the Act,
      except as provided in Section 4 above. Geron has made no representations,
      warranties or covenants whatsoever as to whether any exemption from the
      Act, including, without limitation, any exemption for limited sales in
      routine brokers’ transactions pursuant to Rule 144 under the Act, will
      become available and any such exemption pursuant to Rule 144, if available
      at all, will not be available unless: (i) a public trading market then
      exists in Geron’s common stock, (ii) Geron has complied with the
      information requirements of Rule 144, and (iii) all other terms and
      conditions of Rule 144 have been satisfied.
	 
	 	
            	 	
            	7.5.2	
            	Transfer of the Shares has not been registered or qualified under
      any applicable state law regulating securities and, therefore, the Shares
      cannot and will not be sold unless they are subsequently registered or
      qualified under any such act or an exemption therefrom is available. Geron
      has made no agreements, covenants or undertakings whatsoever to register
      or qualify any of the Shares under any such act. Geron has made no
      representations, warranties or covenants whatsoever as to whether any
      exemption from any such act will become
available.

    

    

    
    

    
      	
            	      	
                    

            	      	
              7.5.3

            	      	Manufacturer hereby certifies that it is an “Accredited
      Investor” as that term is defined in Rule 501 under the Act.
	 
	8.	 	TAX ADVICE. Manufacturer acknowledges
      that Manufacturer has not relied and will not rely upon Geron or Geron’s
      counsel with respect to any tax consequences related to the ownership,
      purchase, or disposition of the Shares. Manufacturer assumes full
      responsibility for all such consequences and for the preparation and
      filing of all tax returns and elections which may or must be filed in
      connection with the Shares.
	 
	9.	 	NOTICES. Any notice or other
      communication required or permitted hereunder shall be in writing and
      shall be deemed to have been duly given on the date of delivery if
      delivered personally or by facsimile, or one day, not including Saturdays,
      Sundays, or national holidays, after sending if sent by national overnight
      delivery service, or five days, not including Saturdays, Sundays, or
      national holidays, after mailing if mailed by first class United States
      mail, certified or registered with return receipt requested, postage
      prepaid, and addressed as follows:

    

    
      	To Geron at:	Geron Corporation
	 	230 Constitution
    Drive
	
            	Menlo Park, California
      94025
	
            	Attention: Senior Director,
      Legal
	
            	Telephone:            
      	(650) 473-7700
	
            	Facsimile:	(650) 473-7750
	 
	To Manufacturer at:	Hongene Biotechnology
      Limited
	
            	Room 203, Building
  8
	
            	No. 500 CaoBao
  Road
	
            	Shanghai, China,
    200233
	
            	Telephone: 0086-21-64757213 or
      0086-21-54971054
	
            	Facsimile:
      0086-21-6470061

    

    
      	10.	      	BINDING
      EFFECT.
      This Agreement shall be binding upon the heirs, legal representatives and
      successors of Geron and of Manufacturer; provided, however, that
      Manufacturer may not assign any rights or obligations under this
      Agreement.
	 
	11.	 	GOVERNING
      LAW. This
      Agreement shall be governed by and construed in accordance with the laws
      of the State of California.
	 
	12.	 	INVALID PROVISIONS.
      In the
      event that any provision of this Agreement is found to be invalid or
      otherwise unenforceable by a court or other tribunal of competent
      jurisdiction, such invalidity or unenforceability shall not be construed
      as rendering any other provision contained herein invalid or
      unenforceable, and all such other provisions shall be given full force and
      effect to the same extent as though the invalid and unenforceable
      provision was not contained herein.
	 
	13.	 	COUNTERPARTS.
      This
      Agreement may be executed in any number of identical counterparts, each of
      which shall be deemed an original, but all of which together shall
      constitute one and the same instrument.
	 
	14.	 	AMENDMENTS. This Agreement or any
      provision hereof may be changed, waived, or terminated only by a statement
      in writing signed by the party against whom such change, waiver or
      termination is sought to be enforced.
	 
	15.	 	FUTURE
      COOPERATION. Each of the parties hereto agrees to cooperate at all times from
      and after the date hereof with respect to all of the matters described
      herein, and to execute such further assignments, releases, assumptions,
      amendments of the Agreement, notifications and other documents as may be
      reasonably requested for the purpose of giving effect to, or evidencing or
      giving notice of, the transactions contemplated by this
    Agreement.

    

    

    
    

    
      	16.	      	ENTIRE
      AGREEMENT.
      This Agreement and the Supply Agreement, including Addendum Agreement No.
      6 thereto, constitute the entire agreement of the parties pertaining to
      the Shares and supersede all prior and contemporaneous agreements,
      representations, and understandings of the parties with respect
      thereto.

    

     

         IN WITNESS WHEREOF, the parties
hereto have executed this Common Stock Purchase Agreement as of the date first
above written.

     

    
      	Geron
    Corporation
	  
	  
	/s/ David L.
      Greenwood
	By:	David L.
Greenwood
	Title:       	Executive Vice
    President
	  	Chief Financial
    Officer
	  	Treasurer and
    Secretary
	   
	Hongene Biotechnology
      Limited
	   
	   
	/s/ Jiang
      Wei
	By:	Jiang Wei
	Title:	General
  Manager

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]